a public good project by the
Synthesis
Company
of California

© 2026

J. M. P. A. van den Reek | doi.page

0 works0 citations0 h-index

J. M. P. A. van den Reek

Radboud University Nijmegen(NL)University Medical Center(US)Radboud University Medical Center(NL)

Publications by Year

Research Areas

Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Health Systems, Economic Evaluations, Quality of Life, Spondyloarthritis Studies and Treatments, Pharmaceutical studies and practices

Most-Cited Works

→ ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTUREnetwork(2014)97 cited
→ An increased risk of non‐melanoma skin cancer during TNF‐inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease‐related factors(2014)66 cited
→ Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry(2016)53 cited
→ Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review(2021)45 cited
→ Determinants of drug survival for etanercept in a long‐term daily practice cohort of patients with psoriasis(2013)41 cited
→ Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis(2024)40 cited

→ Increased incidence of squamous cell carcinoma of the skin after long‐term treatment with azathioprine in patients with auto‐immune inflammatory rheumatic diseases(2012)

39 cited

→ The journey of adult psoriasis patients towards biologics: past and present ‐ Results from the BioCAPTURE registry(2017)32 cited

→ Adalimumab with Methotrexate vs. Adalimumab Monotherapy in Psoriasis: First-Year Results of a Single-Blind Randomized Controlled Trial(2022)31 cited

→ Drug survival for azathioprine and enteric‐coated mycophenolate sodium in a long‐term daily practice cohort of adult patients with atopic dermatitis(2016)29 cited